Amolyt Pharma Announces Abstracts for GRS, ECE, and ENDO Congresses

Amolyt Pharma, a renowned global company dedicated to developing therapeutic peptides for rare endocrine and related diseases, recently announced the acceptance of multiple abstracts for presentation at prominent scientific meetings. These include the 10th International Congress of the Growth Hormone Research Society (GRS) and the 26th European Congress of Endocrinology (ECE) in Stockholm, Sweden, as well as the 2024 Endocrine Society Meeting (ENDO) in Boston, Massachusetts. The presentations will cover Amolyt’s two key development programs: eneboparatide, in Phase 3 trials for hypoparathyroidism, and AZP-3813, in Phase 1 trials for acromegaly.

At the GRS Congress, scheduled for May 10-11, Amolyt will present research on AZP-3813. Specifically, the presentation titled "Additive Effect of Combined Treatment with the Small Peptide GH Receptor Antagonist, AZP-3813, and the Somatostatin Analog, Octreotide, in Decreasing IGF1 Levels in the Rat" will discuss findings from an oral session on acromegaly.

From May 11-14, at the ECE, Amolyt will share several presentations. These include a mini satellite symposium on "Renal Complications in Chronic Hypoparathyroidism" and various oral presentations covering topics such as prolonged calcium normalization induced by eneboparatide, increased urinary calcium excretion, nephrolithiasis, and secretions of parathyroid hormone in chronic hypoparathyroidism. Additionally, findings from a Phase 1 clinical study evaluating the safety and efficacy of AZP-3813 will be detailed in a rapid communication session.

The ECE will also feature poster presentations on the combined treatment effects of AZP-3813 and octreotide, and real-world data on increased bone fragility in women with chronic hypoparathyroidism.

At the ENDO meeting, from June 1-4, Amolyt will present several significant studies. One presentation will cover the Phase 1 clinical study of AZP-3813, focusing on its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. Other presentations will include discussions on skeletal effects in women with hypoparathyroidism, the increased fragility of bones in female patients with chronic hypoparathyroidism, and the enhanced effectiveness of AZP-3813 when combined with octreotide. An oral presentation will also explore how eneboparatide stimulates urinary calcium reabsorption and induces prolonged renal cortex retention and PTH1 receptor signaling.

Amolyt Pharma, a clinical-stage biotechnology company, builds on its expertise to develop life-changing treatments for patients with rare endocrine and related diseases. Its development portfolio features eneboparatide, a long-acting PTH1 receptor agonist with potential as a treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist aimed at treating acromegaly. The company continues to expand its portfolio through its extensive network in endocrinology and strong international investor support.

These presentations at key scientific conferences underscore Amolyt Pharma's commitment to advancing research and therapeutic options for endocrine diseases, highlighting the company's progress and innovative approach in the field.